X0306 4 2016-02-01 0 0000827871 EAGLE PHARMACEUTICALS, INC. EGRX 0001469124 Tarriff Scott C/O EAGLE PHARMACEUTICALS, INC. 50 TICE BLVD., SUITE 315 WOODCLIFF LAKE NJ 07677 1 1 0 0 President and CEO Common Stock 2016-02-01 4 S 0 5367 66.03 D 1433484 D Common Stock 2016-02-01 4 S 0 3600 67.46 D 1429884 D Common Stock 2016-02-01 4 S 0 5260 68.52 D 1424624 D Common Stock 2016-02-01 4 S 0 2431 69.95 D 1422193 D Common Stock 2016-02-01 4 S 0 1702 71.84 D 1420491 D These shares were sold pursuant to a Rule 10b5-1 trading plan dated as of June 19, 2015. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.80 to $66.48, inclusive. The reporting person undertakes to provide to Eagle Pharmaceuticals, Inc., any security holder of Eagle Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) and in footnotes (3)-(6). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.11 to $68.04, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $68.11 to $69.09, inclusive The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $69.25 to $70.16, inclusive The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $71.67 to $72.20, inclusive /s/ David E. Riggs, Attorney-in-Fact 2016-02-02